Trevi Therapeutics (TRVI) Amortization of Deferred Charges (2018 - 2026)

Trevi Therapeutics' Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $105000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 6.25% year-over-year to $105000.0 in Q1 2026; TTM through Mar 2026 was $430000.0, a 4.87% decrease from a year earlier, with the FY2025 full-year figure at $437000.0, down 5.0% from the prior year.
• Amortization of Deferred Charges eased to $105000.0 in Q1 2026 per TRVI's latest filing, from $107000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $420000.0 in Q4 2022 and bottomed at -$87000.0 in Q2 2022.
• The 5-year median for Amortization of Deferred Charges is $108000.0 (2025), against an average of $111705.9.
• Across the five-year window, Amortization of Deferred Charges tumbled 159.59% in 2022 and soared 272.41% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $420000.0 in 2022, then plunged by 71.9% to $118000.0 in 2023, then soared by 67.8% to $198000.0 in 2024, then slumped by 45.96% to $107000.0 in 2025, then dropped by 1.87% to $105000.0 in 2026.
• Per Business Quant, the three latest TRVI Amortization of Deferred Charges figures stand at $105000.0 (Q1 2026), $107000.0 (Q4 2025), and $108000.0 (Q3 2025).